Karol Kaltenbach1, Kevin E O'Grady2, Sarah H Heil3, Amy L Salisbury4, Mara G Coyle5, Gabriele Fischer6, Peter R Martin7, Susan Stine8, Hendrée E Jones9. 1. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA. Electronic address: Karol.Kaltenbach@jefferson.edu. 2. Department of Psychology, University of Maryland, College Park, College Park, MD 20742, USA. Electronic address: ogrady@umd.edu. 3. Departments of Psychiatry and Psychology, University of Vermont, Burlington, VT, USA. Electronic address: sarah.heil@uvm.edu. 4. Brown Center for the Study of Children at Risk, Women and Infants' Hospital, Providence, RI, USA; Department of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI, USA; Department of Psychiatry and Human Behavior, The Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: asalisbury@wihri.org. 5. Department of Pediatrics, The Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: mcoyle@wihri.org. 6. Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria. Electronic address: gabriele.fischer@meduniwien.ac.at. 7. Department of Psychiatry, Vanderbilt University, Nashville, TN, USA. Electronic address: peter.martin@vanderbilt.edu. 8. Emeritus Professor of Psychiatry and Behavior Neurosciences, Wayne State University, Detroit, MI, USA. Electronic address: sstine@med.wayne.edu. 9. UNC Horizons and Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA; Departments of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology, School of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA. Electronic address: Hendree_Jones@med.unc.edu.
Abstract
BACKGROUND:Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy. However, the literature on the relationship between longer-term effects of prenatal exposure to these medications and childhood development is both spare and inconsistent. METHODS:Participants were 96 children and their mothers who participated in MOTHER, a randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. The present study examined child growth parameters, cognition, language abilities, sensory processing, and temperament from 0 to 36 months of the child's life. Maternal perceptions of parenting stress, home environment, and addiction severity were also examined. RESULTS: Tests of mean differences between children prenatally exposed to methadone vs. buprenorphine over the three-year period yielded 2/37 significant findings for children. Similarly, tests of mean differences between children treated for NAS relative to those not treated for NAS yielded 1/37 significant finding. Changes over time occurred for 27/37 child outcomes including expected child increases in weight, head and height, and overall gains in cognitive development, language abilities, sensory processing, and temperament. For mothers, significant changes over time in parenting stress (9/17 scales) suggested increasing difficulties with their children, notably seen in increasing parenting stress, but also an increasingly enriched home environment (4/7 scales) CONCLUSIONS: Findings strongly suggest no deleterious effects of buprenorphine relative to methadone or of treatment for NAS severity relative to not-treated for NAS on growth, cognitive development, language abilities, sensory processing, and temperament. Moreover, findings suggest that prenatal opioid agonist exposure is not deleterious to normal physical and mental development.
RCT Entities:
BACKGROUND:Methadone and buprenorphine are recommended to treat opioid use disorders during pregnancy. However, the literature on the relationship between longer-term effects of prenatal exposure to these medications and childhood development is both spare and inconsistent. METHODS:Participants were 96 children and their mothers who participated in MOTHER, a randomized controlled trial of opioid-agonist pharmacotherapy during pregnancy. The present study examined child growth parameters, cognition, language abilities, sensory processing, and temperament from 0 to 36 months of the child's life. Maternal perceptions of parenting stress, home environment, and addiction severity were also examined. RESULTS: Tests of mean differences between children prenatally exposed to methadone vs. buprenorphine over the three-year period yielded 2/37 significant findings for children. Similarly, tests of mean differences between children treated for NAS relative to those not treated for NAS yielded 1/37 significant finding. Changes over time occurred for 27/37 child outcomes including expected child increases in weight, head and height, and overall gains in cognitive development, language abilities, sensory processing, and temperament. For mothers, significant changes over time in parenting stress (9/17 scales) suggested increasing difficulties with their children, notably seen in increasing parenting stress, but also an increasingly enriched home environment (4/7 scales) CONCLUSIONS: Findings strongly suggest no deleterious effects of buprenorphine relative to methadone or of treatment for NAS severity relative to not-treated for NAS on growth, cognitive development, language abilities, sensory processing, and temperament. Moreover, findings suggest that prenatal opioid agonist exposure is not deleterious to normal physical and mental development.
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Justine N Whitham; Nicola J Spurrier; Michael G Sawyer; Peter A Baghurst; John E Taplin; Jason M White; Andrea L Gordon Journal: Neurotoxicol Teratol Date: 2009-09-12 Impact factor: 3.763
Authors: Hendrée E Jones; Gabriele Fischer; Sarah H Heil; Karol Kaltenbach; Peter R Martin; Mara G Coyle; Peter Selby; Susan M Stine; Kevin E O'Grady; Amelia M Arria Journal: Addiction Date: 2012-11 Impact factor: 6.526
Authors: Barbara K Zedler; Ashley L Mann; Mimi M Kim; Halle R Amick; Andrew R Joyce; E Lenn Murrelle; Hendrée E Jones Journal: Addiction Date: 2016-06-30 Impact factor: 6.526
Authors: Charles R Bauer; John Langer; Brittany Lambert-Brown; Seetha Shankaran; Henrietta S Bada; Barry Lester; Lynn L Lagasse; Toni Whitaker; Jane Hammond Journal: J Perinatol Date: 2020-05-22 Impact factor: 2.521
Authors: Ludmila N Bakhireva; Bradley D Holbrook; Shikhar Shrestha; Yuridia Leyva; Malia Ashley; Sandra Cano; Jean Lowe; Julia M Stephen; Lawrence Leeman Journal: Early Hum Dev Date: 2018-12-13 Impact factor: 2.079
Authors: Julia Brennan; Caleb Wiedeman; John R Dunn; William Schaffner; Timothy F Jones Journal: Public Health Rep Date: 2019-08-07 Impact factor: 2.792
Authors: Marian P Jarlenski; Elizabeth E Krans; Joo Yeon Kim; Julie M Donohue; A Everette James; David Kelley; Bradley D Stein; Debra L Bogen Journal: Health Aff (Millwood) Date: 2020-02 Impact factor: 6.301
Authors: Kathryn G Beauchamp; Jean Lowe; Ronald M Schrader; Shikhar Shrestha; Crystal Aragón; Natalia Moss; Julia M Stephen; Ludmila N Bakhireva Journal: Early Hum Dev Date: 2020-07-02 Impact factor: 2.079